European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

European markets are expected to open in negative territory on Wednesday, with investors looking ahead to more earnings from ...

Ahead of his confirmation hearing this week, Robert F. Kennedy Jr., President Donald Trump’s nominee for HHS Secretary, has ...

Decades into her legendary career, actress, model, author and businesswoman Brooke Shields is busier than ever before. The star just published her book Brooke Shields Is Not Allowed to Get Old: ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said it ...

GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare Conference, the European healthcare giant noted there ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to $1.15bn in cash, marking the first ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

NN was so flexible that you could use a modified version to teach journalism skills, like interviewing, fact-checking, and being beaten to death by goblins you accidentally triggered when you ...

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based ...